TD Cowen reiterates buy on Compass Pathways stock, $29 target By Investing.com

CMPS is the obvious beneficiary, but the more important read-through is that the regulatory path is now functionally de-risked in two dimensions at once: FDA timeline compression and DEA sequencing. That matters because it pulls forward not just approval probability, but the capital markets window for a pre-launch re-rate; in this setup, the stock can keep grinding higher on process milestones even before any commercial revenue is visible. The move also implicitly raises the value of every adjacent psychedelic program, but especially those with cleaner CMC and trial packages that could qualify for similar regulatory acceleration.

The second-order winner may be contract development/manufacturing and trial-enablement vendors that can absorb near-term sponsor demand without needing the same binary de-risking. Conversely, pure-play competitors in depression and neuropsychiatry with later-stage assets but less differentiated regulatory positioning may see relative multiple compression as capital rotates toward the first potential approvable platform. If CMPS is treated as the lead indicator, expect a widening spread between names with a visible path to registration and those still stuck in mid-stage proof-of-concept.

The market is likely underpricing timeline risk more than approval risk. Even with accelerated review, the meaningful gap is still between headline optimism and actual commercial launch, which can easily remain a 12-18 month story if DEA, labeling, REMS, or site-readiness issues slow execution. The trade is therefore less about chasing the stock after a 37% week and more about owning optionality into the next two catalysts while keeping tight downside discipline if the company slips on protocol details or if the agency process proves less parallel than hoped.

Near term, the move can extend on analyst target resets and incremental regulatory commentary, but the risk/reward deteriorates quickly if the stock begins discounting a perfect outcome. The contrarian view is that the street may be front-loading a 2026 approval case that still depends on a novel treatment paradigm, and those programs often face softer-than-expected adoption even after approval. That makes this a classic event-driven momentum name with a long-duration fundamental payoff, not a clean “buy and forget” healthcare story.